P31 Impact of COVID-19 on HTA/PRMA of Medicinal Products in Europe: A Payer Perspective

Abstract

Authors

J Mycka R Dellamano W Lobb N Dalal L Dellamano E Pereira

Full Text Cite This Article
Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×